Brief: Tetra Bio Pharma Obtains Health Canada Approval To Conduct A Phase 1 Pharmacokinetic & Safety Study Using Vaporized Version Of PPP001
01/11/2018 10:57
Nov 1 (Reuters) - Tetra Bio Pharma Inc TBP.V :
* TETRA BIO-PHARMA OBTAINS HEALTH CANADA APPROVAL TO CONDUCT
A
PHASE 1 PHARMACOKINETIC & SAFETY STUDY USING VAPORIZED VERSION
OF PPP001
* TETRA BIO PHARMA INC - STUDY IS EXPECTED TO BEGIN AND END
IN Q4
2018.
Source text for Eikon: ID:nGNX302rKk
Further company coverage: TBP.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tetra Bio Pharma
See all newsBrief: Tetra Bio Receives A Second Clarifax From Health Canada Regarding Reduvo Risk Management Plan
Brief: Tetra Bio-Pharma Announces Results Of Artificial Intelligence Study Of ARDS-003 Combined With Favipiravir
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra And Prepaire Jointly Apply To Barda For Funding